Niloufer Khan, M.D.

Hematologist and oncologist Niloufer Khan, M.D., was inspired by her mother, a physician, to pursue a medical career. Dr. Khan understands that a cancer diagnosis is a life-changing and frightening moment for patients, and she is proud to serve as their advocate and guide during treatment. Her goal is to give her patients a clear understanding of their diagnosis, treatment options and resources for care at City of Hope. Along with the other members of the care team, she is committed to helping her patients to feel as well as possible, so they can experience a life that is not limited by their diagnosis.    

Dr. Khan completed her undergraduate education and medical school at Case Western Reserve University in Cleveland, where she graduated with honors.  She completed a residency in internal medicine/pediatrics  at the University of Chicago and a fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. Prior to coming to City of Hope, Dr. Khan was a faculty member on the Lymphoma Service at Memorial Sloan Kettering Cancer Center.  

A lymphoma expert, Dr. Khan came to City of Hope to work with a world-class, multidisciplinary team to deliver high-quality, leading-edge, compassionate and personalized care to her patients. Her research is focused on improving quality of life for people with lymphoma. She has a special interest in caring for adolescent and young adult (AYA) patients. These patients are diagnosed with cancer at a formative period in their lives. In addition to excellent cancer care that is targeted to their age group, AYA patients need care for their unique psychological, developmental and social needs. She is also involved in clinical trials to find new and better ways to treat rare lymphomas, such as T cell, Hodgkin and cutaneous lymphomas.

She is a Lymphoma Research Foundation Scholar, and in 2018, she received the American Society of Clinical Oncology’s Young Investigator Award.

Dr. Khan enjoys reading, hiking, cooking and exploring new restaurants in her free time.
 

• Stuver R, Epstein-Peterson ZD, Johnson WT, Khan N, Lewis N, Moskowitz AJ, Sauter CS, Horwitz S. Current Treatment of Peripheral T-cell Lymphoma. Oncology (Williston Park). 2022 May 9; 36(5): 293-305. PMID: 35576176.
• Sha F, Okwali M, Alperovich A, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Khan N, Kumar A, Matasar MJ, Moskowitz AJ, Noy A, Owens C, Palomba LM, Rodriguez-Rivera I, Straus D, von Keudell G, Zelenetz AD, Yahalom J, Dogan A, Schöder H, Seshan VE, Salles G, Younes A, Batlevi CL. Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. Blood Cancer J. 2022 Feb 10; 12(2). PMID: 35145059
• Salant JA, Khan N, Nelson JE, Norton-Westbrook M, Desai AV. Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Cutaneous T Cell Lymphoma. J Palliat Med. 2021 Jun; 25(6) 958-963. PMID: 34978848.
• Khan N, Noor S, Horwitz S. How we treat mycosis fungoides and Sezary syndrome. Clin Adv Hematol Oncol. 2021 Sep; 19(9): 573-581. PMID: 34495021.
• Kumar A, Casulo C, Advani RH, Budde E, Barr PM, Batlevi CL, Caron P, Constine LS, Dandapani SV, Drill E, Drullinsky P, Friedberg JW, Grieve C, Hamilton A, Hamlin PA, Hoppe RT, Horwitz SM, Joseph A, Khan N, Laraque L, Matasar MJ, Moskowitz AJ, Noy A, Palomba ML, Schöder H, Straus DJ, Vemuri S, Yang J, Younes A, Zelenetz AD, Yahalom J, Moskowitz CH. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. J Clin Oncol. 2021 Apr 28:JCO2100108. doi: 10.1200/JCO.21.00108. Epub ahead of print. PMID: 33909449.
• Khan N, Lindner S, Gomes ALC, Devlin SM, Shah GL, Sung AD, Sauter CS, Landau HJ, Dahi PB, Perales MA, Chung DJ, Lesokhin AM, Dai A, Clurman A, Slingerland JB, Slingerland AE, Brereton DG, Giardina PA, Maloy M, Armijo GK, Rondon-Clavo C, Fontana E, Bohannon L, Ramalingam S, Bush AT, Lew MV, Messina JA, Littmann E, Taur Y, Jenq RR, Chao NJ, Giralt S, Markey KA, Pamer EG, van den Brink MRM, Peled JU. Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. Blood. 2021 Mar 18;137(11):1527-1537. doi: 10.1182/blood.2020006923. PMID: 33512409; PMCID: PMC7976512
• Khan N, Feliciano J, Müller K, He M, Tao R, Korol E, Dalal M, Rebeira M, Matasar M. Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment. Leuk Lymphoma. 2020 Jul 20:1-8. doi: 0.1080/10428194.2020.1783443. PMID: 32684056.
• Thom B, Mamoor M, Lavery JA, Baxi SS, Khan N, Rogak LJ, Sidlow R, Korenstein D. The experience of financial toxicity among advanced melanoma patients treated with immunotherapy. J Psychosoc Oncol. 2020 Oct 26:1-9. doi: 10.1080/07347332.2020.1836547. Online ahead of print. PMID: 33103948.
• Mamoor M, Postow MA, Lavery JA, Baxi SS, Khan N, Mao JJ, Rogak LJ, Sidlow R, Thom B, Wolchok JA, Korenstein D. Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors. J Immunother Cancer. 2020 Mar;8(1):e000260. doi: 10.1136/jitc-2019-000260. PMID: 32152222.
• Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, Weber D, Hashimoto D, Slingerland AE, Slingerland JB, Maloy M, Clurman AG, Stein-Thoeringer CK, Markey KA, Docampo MD, Burgos da Silva M, Khan N, Gessner A, Messina JA, Romero K, Lew MV, Bush A, Bohannon L, Brereton DG, Fontana E, Amoretti LA, Wright RJ, Armijo GK, Shono Y, Sanchez-Escamilla M, Castillo Flores N, Alarcon Tomas A, Lin RJ, Yáñez San Segundo L, Shah GL, Cho C, Scordo M, Politikos I, Hayasaka K, Hasegawa Y, Gyurkocza B, Ponce DM, Barker JN, Perales MA, Giralt SA, Jenq RR, Teshima T, Chao NJ, Holler E, Xavier JB, Pamer EG, van den Brink MRM. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020 Feb 27;382(9):822-834.
• Stuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C, Horwitz SM, Lansigan F, Pinter-Brown LC, Pro B, Shustov AR, Foss FM, Jain S. Single Agents Versus Combination Chemotherapy in Relapsed and Refractory Peripheral T-cell Lymphoma: Results from the Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) Registry. Am J Hematol. 2019 Jun;94(6):641-649.
• Khan N, Horwitz S. Immunotherapy in mycosis fungoides: opening night or dress rehearsal? Leuk Lymphoma. 2019 Apr;60(4):864-866.
• Khan N, Ozkaya N, Moskowitz A, Dogan A, Horwitz S. Peripheral T-cell lymphoma – are we making progress? Best Pract Res Clin Haematol. 2018 Sep;31(3):306-314.
• Baxi S, Yang A, Gennarelli R, Khan N, Boyce L, Korenstein D. Immune-related Toxicities in PD-1 and PD-L1 Immunotherapies: a Systematic Review and Metaanalysis. BMJ. 2018 Mar 14;360:k793.
• Khan N, Moskowitz AJ. Where do the new drugs fit in for relapsed/refractory Hodgkin lymphoma? Curr Hematol Malig Rep. 2017 Jun;12(3):227-233.